Entellus Medical Inc (NASDAQ:ENTL) VP Thomas P. Williamson sold 968 shares of the stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $24.01, for a total transaction of $23,241.68. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Thomas P. Williamson also recently made the following trade(s):

  • On Monday, January 8th, Thomas P. Williamson sold 2,449 shares of Entellus Medical stock. The stock was sold at an average price of $24.08, for a total transaction of $58,971.92.

Entellus Medical Inc (NASDAQ ENTL) traded down $0.08 during trading hours on Tuesday, hitting $24.28. 134,509 shares of the stock were exchanged, compared to its average volume of 246,683. Entellus Medical Inc has a twelve month low of $11.47 and a twelve month high of $25.58. The company has a market cap of $618.51 and a PE ratio of -18.97. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32.

Several large investors have recently added to or reduced their stakes in the company. Kopp Investment Advisors LLC boosted its holdings in shares of Entellus Medical by 0.5% in the 2nd quarter. Kopp Investment Advisors LLC now owns 11,874 shares of the medical technology company’s stock valued at $197,000 after buying an additional 55 shares in the last quarter. Nationwide Fund Advisors boosted its holdings in shares of Entellus Medical by 61.7% in the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after buying an additional 2,635 shares in the last quarter. Keybank National Association OH boosted its holdings in shares of Entellus Medical by 11.0% in the 2nd quarter. Keybank National Association OH now owns 32,594 shares of the medical technology company’s stock valued at $540,000 after buying an additional 3,235 shares in the last quarter. Cypress Capital Management LLC WY boosted its holdings in shares of Entellus Medical by 5.4% in the 3rd quarter. Cypress Capital Management LLC WY now owns 66,965 shares of the medical technology company’s stock valued at $1,236,000 after buying an additional 3,425 shares in the last quarter. Finally, California State Teachers Retirement System boosted its holdings in shares of Entellus Medical by 26.4% in the 2nd quarter. California State Teachers Retirement System now owns 21,517 shares of the medical technology company’s stock valued at $356,000 after buying an additional 4,500 shares in the last quarter. Institutional investors and hedge funds own 78.76% of the company’s stock.

Several research analysts have issued reports on ENTL shares. Canaccord Genuity reiterated a “hold” rating and set a $17.00 target price on shares of Entellus Medical in a report on Tuesday, October 17th. Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 target price on the stock in a report on Monday, October 9th. TheStreet upgraded shares of Entellus Medical from a “d” rating to a “c-” rating in a report on Thursday, December 14th. ValuEngine upgraded shares of Entellus Medical from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Finally, William Blair cut shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a report on Friday, December 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $19.25.

TRADEMARK VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/01/09/thomas-p-williamson-sells-968-shares-of-entellus-medical-inc-entl-stock.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Stock Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related stocks with our FREE daily email newsletter.